Targets › IRAK4
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. (UniProt, Q9NWZ3)
Open in Phaseline: the race on IRAK4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hangzhou Polymed Biopharmaceuticals | HPB-092 FLT3 and IRAK4 inhibitor | FLT3, IRAK4 | Phase 1 | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Jun 2027 |
| AstraZeneca | AZD2962 IRAK4 inhibitor | IRAK4 | Phase 1 | Haematologic Neoplasms | Oct 2028 |
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) (1) Haematologic Neoplasms (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.